At the 2016 Transforming Healthcare conference, one panel focused on value. From left: Jane Sarasohn-Kahn, health economist/advisor, THINK-Health; Jessica Brueggeman, SVP of the health behavior group at MicroMass Communications; Shelly Ikeme, global head of market access, health economics, and international pricing at Baxter; and Dr. Leonard Saltz, chairman of the pharmacy and therapeutics committee, Memorial Sloan Kettering Cancer Center. Photo credit: Erica Berger

MM&M will host the third annual Transforming Healthcare conference, a one-day event devoted to the concept of beyond-the-pill partnerships, strategies, and rationale.

There’s an urgency driving biopharma companies to go down this path, said Dr. Gautam Gulati, an innovation expert who will give the keynote address at the conference, scheduled May 1 in New York City. Gulati is renowned for his ability to transform organizations — both big and small — to meet the future innovative demands of the health industry.

“The biopharmaceutical industry is at a critical ‘do or die’ moment,” he said. “Pressure on cost and pricing is mounting, and new unconventional competitors are threatening to encroach on their territory. Going beyond the pill will require us to entirely reshape our thinking from ‘products solving problems’ to ‘experiences designed for people.'”

Learn more about the 2017 MM&M Transforming Healthcare conference. 

Biopharma and medical device firms on the hunt for services to support their therapies will discover an abundance of use cases and early stage design expertise at Transforming Healthcare. A new conference advisory board — comprised of digital strategy and enterprise innovation experts from firms including AstraZeneca, Biogen, and Takeda Pharmaceuticals — has collaborated with MM&M to curate an agenda for life sciences professionals.

The conference will focus on themes like innovation throughout the product lifecycle, from digitally infused R&D to launching a digital therapy, and the growing pains of integrating a data-science culture into a traditional pharma environment.

Speakers range from medical futurists and payer executives to the founders of health-tech startups, patients, and the heads of biopharma innovation labs, as well as members of MM&M’s Top 40 Healthcare Transformers. The 2017 class of Transformers will be announced in April.

Notable speakers include Daniel Gandor, head of the digital accelerator at Takeda Pharmaceuticals, and Deborah Profit, leader of IT at Otsuka Pharmaceutical.

As value-based, pay-for-performance, and bundled payments become more common, healthcare companies and brands must adopt enhancements to the drugs, biologic therapies, or medical devices they sell, in order to improve outcomes for patients and help organizations drive down costs.

The agenda is designed with practicality in mind: to help attendees go back to their organizations with the tools they need to create experiences that allow their customers to have more engagement with products. The event also helps break down silos between biopharma companies and the rest of the healthcare ecosystem through a variety of interactive formats.

The conference will once again feature a shark-tank style segment, now known as the Startup Showdown, in which health-tech startups pitch live before the audience to a panel of biopharma marketers for a chance at a potential beyond-the-pill contract.

As pharma and the life sciences start to embrace the new role of patients and their expectations for digital technology — areas that are not so new for other areas of healthcare — the MM&M Transforming Healthcare conference creates a venue for stakeholders to share data, case studies, and technology.

Dr. Gulati, who has held various executive posts as chief innovation officer and serves as adjunct faculty at the Johns Hopkins Carey Business School, Duke Corporate Education, and Singularity University, stressed the need for industry to take transformation seriously.

“Simply fine-tuning existing ways of doing business is no longer sufficient,” he added. “To successfully inoculate against the uncertainties of the future, biopharmaceutical and medical device companies will need to adopt entirely new models of thinking that can help transform both their business and culture from the inside, out.”

For sponsorship opportunities, email [email protected].